- Home
- ACIU vs IMMR Comparison
ACIU vs IMMR Comparison
Compare ACIU & IMMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- IMMR
- Stock Information
- Founded
- ACIU 2003
- IMMR 1993
- Country
- ACIU Switzerland
- IMMR United States
- Employees
- ACIU N/A
- IMMR N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- IMMR Computer peripheral equipment
- Sector
- ACIU Health Care
- IMMR Technology
- Exchange
- ACIU Nasdaq
- IMMR Nasdaq
- Market Cap
- ACIU 213.3M
- IMMR 229.4M
- IPO Year
- ACIU 2016
- IMMR 1999
- Fundamental
- Price
- ACIU $3.36
- IMMR $6.81
- Analyst Decision
- ACIU Strong Buy
- IMMR Strong Buy
- Analyst Count
- ACIU 2
- IMMR 2
- Target Price
- ACIU $10.00
- IMMR $12.25
- AVG Volume (30 Days)
- ACIU 417.2K
- IMMR 416.3K
- Earning Date
- ACIU 11-04-2025
- IMMR 12-15-2025
- Dividend Yield
- ACIU N/A
- IMMR 2.62%
- EPS Growth
- ACIU N/A
- IMMR 57.07
- EPS
- ACIU N/A
- IMMR 2.04
- Revenue
- ACIU $5,482,957.00
- IMMR $163,133,000.00
- Revenue This Year
- ACIU N/A
- IMMR $988.71
- Revenue Next Year
- ACIU $1,022.98
- IMMR $109.72
- P/E Ratio
- ACIU N/A
- IMMR $3.37
- Revenue Growth
- ACIU N/A
- IMMR 338.21
- 52 Week Low
- ACIU $1.43
- IMMR $6.36
- 52 Week High
- ACIU $4.00
- IMMR $10.72
- Technical
- Relative Strength Index (RSI)
- ACIU 53.82
- IMMR 46.91
- Support Level
- ACIU $3.20
- IMMR $6.36
- Resistance Level
- ACIU $3.70
- IMMR $6.93
- Average True Range (ATR)
- ACIU 0.40
- IMMR 0.19
- MACD
- ACIU -0.01
- IMMR 0.01
- Stochastic Oscillator
- ACIU 53.28
- IMMR 58.34
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About IMMR Immersion Corporation
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.